Health Condition 1: K746- Other and unspecified cirrhosis ofliver
Conditions
Interventions
Intervention1: GROUP 1 BCAA: 1.2 g L-leucine
0.6 g L-isoleucine
0.6 g L-valine
5.7 g Saccharose
BD FOR 6 MONTHS
Intervention2: GROUP 1 BCAA: 1.2 g L-leucine
0.6 g L-isoleucine
0.6 g L-valine
Sacchar
Sponsors
Nims University Rajasthan Jaipur India
Eligibility
Inclusion criteria
Inclusion criteria: 1 Male and female patients between 18 and 70 years of age 2 Patients with a recorded diagnosis of cirrhosis (clinical, biochemical, radiological and endoscopy) 3 Patients willing to participate in the study by signing the informed consent form 4 Decompensated cirrhotic patient under Child Pugh score 7-12 (Grade B & Grade C)
Exclusion criteria
Exclusion criteria: 1 Patients with history of alcohol intake during the past 6 weeks 2 Patients having active malignant disease, hepatocellular carcinoma, acute liver failure, heart failure, renal failure, end-stage chronic obstructive lung disease, diabetes. 3 Patients with previous transjugular intrahepatic portosystemic shunt or those who underwent a shunt or those who underwent a shunt 4 Patients with a considerable comorbid illness, such as heart, respiratory, or renal failure 5 Patients with neurologic diseases, such as Alzheimerâ??s disease, Parkinsonâ??s disease 6 Patients with non-hepatic metabolic encephalopathies 7 Patients on psychoactive drugs, such as antidepressants or sedatives 8 Any condition that in the opinion of the investigator does not justify the patientâ??s inclusion in the study 9 Those patients who are immunocompromised. 10 Cirrhotic patients with a serum albumin of >=3.6g/dl. 11 Comatose / Stupor Pose /Intubated patients. 12 Pregnant and breast-feeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in nutritional parameters, Liver function tests (specifically for albumin synthesis), Child Pughâ??s Score / MELD Score and Health related Quality of Life (HRQOL).Timepoint: Baseline, 4 Weeks, 12 Weeks, 24 Weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes will be assessed by measuring reduction in number of hospital admissions, Number of days of hospital stay, Rate of hospitalization and development of Hepatic Encephalopathy/death.Timepoint: Baseline, 4 Weeks, 12 Weeks, 24 Weeks | — |
Countries
India
Contacts
Public ContactDeepak Nathiya
Department of Pharmacy Practice
Outcome results
None listed